Aβ accumulation plays a central role in the pathogenesis of Alzheimer's disease (AD). Recent studies suggest that the process of Aβ nucleated polymerization is essential for Aβ fibril formation, pathology spreading and toxicity. Therefore, targeting this process represents an effective therapeutic strategy to slow or block disease progression. To discover compounds that might interfere with the Aβ seeding capacity, toxicity and pathology spreading, we screened a focused library of FDA-approved drugs in vitro using a seeding polymerization assay and identified small molecule inhibitors that specifically interfered with Aβ seeding-mediated fibril growth and toxicity. Mitoxantrone, bithionol and hexachlorophene were found to be the strongest inhibitors of fibril growth and protected primary cortical neuronal cultures against Aβ-induced toxicity. Next, we assessed the effects of these three inhibitors in vivo in the mThy1-APPtg mouse model of AD (8-month-old mice). We found that mitoxantrone and bithionol, but not hexachlorophene, stabilized diffuse amyloid plaques, reduced the levels of Aβ 42 oligomers and ameliorated synapse loss, neuronal damage and astrogliosis. Together, our findings suggest that targeting fibril growth and Aβ seeding capacity constitutes a viable and effective strategy for protecting against neurodegeneration and disease progression in AD.
Introduction
Evidence from genetics, neuropathology, biochemistry and animal models continues to suggest that amyloid β protein (Aβ) aggregation and amyloid formation play central roles in the initiation and progression of neurodegeneration in Alzheimer's disease (AD) (Hartley et al., 1999; McLean et al., 1999) . However, the mechanisms by which these processes contribute to the pathogenesis of AD and the nature of the toxic species remain subjects of active investigation and debate. Genetic mutations (Goate et al., 1991; Lemere et al., 1996; Nilsberth et al., 2001) or changes in the neurons that result in the increased production of Aβ or enhanced fibril formation have been linked to early onset forms of AD (McLean et al., 1999; Kumar-Singh et al., 2006) .
Aβ is produced as a result of sequential proteolytic cleavage of the amyloid precursor proteins by β-and γ-secretase (Selkoe, 2012) resulting in the generation of Aβ peptides of variable lengths, with Aβ 40 being the predominate species and Aβ 42 being the most amyloidogenic and toxic form (Duyckaerts et al., 2009; Mucke et al., 2000) . Aβ fibril formation occurs via multiple mechanisms involving primary and secondary nucleation events and involves the formation of on or off-pathway oligomers.
The nucleated polymerization mechanism (Fig. 1 ) is characterized by a nucleation phase associated with the formation of assembly competent oligomers followed by a cooperative oligomer growth and fibril formation by monomer addition (Harper and Lansbury, 1997). Several oligomeric intermediates of different morphologies, including spherical, chain-like, and annular oligomers have been observed during Aβ fibril formation in vitro (Jan et al., 2010b) , and similar structures were identified during post-mortem biochemical analysis of AD brains (Lemere et al., 1996; Lesne et al., 2006) . This process of Aβ fibril formation can be seeded and accelerated by the addition of preformed fibrils (Fig. 1) . The addition of a small amount of preformed fibrillar aggregates (seeds) eliminates the lag phase of Aβ aggregation and accelerates the fibrillization of monomeric Aβ in vitro and in vivo (Harper and Lansbury, 1997) . The pathological relevance and consequences of this process remain subjects of intense debate and active investigation. We have recently shown that the toxicity of
